Search Result

Results for "

VEGFR-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (9) Autophagy (13) Bcr-Abl (1) c-Fms (3) c-Kit (30) c-Met/HGFR (2) Complement System (2) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Metabolite (6) EGFR (4) FGFR (35) FLT3 (10) IKK (1) Interleukin Related (1) Isotope-Labeled Compounds (7) Necroptosis (1) NO Synthase (3) PARP (1) PD-1/PD-L1 (1) PDGFR (40) PKA (1) PKC (4) Raf (9) Reference Standards (20) RET (16) RIP kinase (1) Src (1) Syk (1) Tie (5) TNF Receptor (1) Topoisomerase (1) VEGFR (79)
By Research Areas:	Cancer (80) Cardiovascular Disease (3) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10981

Lenvatinib Maximum Cited Publications 92 Publications Verification E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-50904

Nintedanib 70+ Cited Publications BIBF 1120	PDGFR VEGFR FGFR	Cancer
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10331

Regorafenib 85+ Cited Publications BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for *VEGFR1/2/3, PDGFRβ, Kit, RET* and *Raf-1*, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity ^[1].

HY-10374

Semaxinib 70+ Cited Publications SU5416	VEGFR	Cancer
Semaxinib (SU5416) is a potent and selective inhibitor of *VEGFR* (Flk-1/KDR) with an IC₅₀ of 1.23 μM ^[1].

HY-11106

Nintedanib esylate 70+ Cited Publications BIBF 1120 esylate	PDGFR VEGFR FGFR	Cancer
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10230

Midostaurin 35+ Cited Publications PKC412; CGP 41251	PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, *Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ* and *VEGFR1/2* with IC₅₀s ranging from 22-500 nM ^[1] . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-10977

Tivozanib 5+ Cited Publications AV-951; KRN951	VEGFR	Cancer
Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy ^[1].

HY-112306

Ripretinib 5+ Cited Publications DCC-2618	c-Kit PDGFR FLT3 VEGFR Apoptosis	Cancer
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .

HY-12297

Sulfatinib 2 Publications Verification SurufatINib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against *VEGFR1/2/3, FGFR1* and *CSF1R* with IC₅₀s of in a range of 1 to 24 nM.

HY-50905

Dovitinib 10+ Cited Publications CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3* and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity ^[1] .

HY-10981A

Lenvatinib mesylate Maximum Cited Publications 92 Publications Verification E7080 mesylate	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-16135

CEP-11981 ESK981; BOL 303213X	VEGFR FGFR	Cancer
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, *VEGFR1-3* and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects ^[1].

HY-10799

EG00229 trifluoroacetate 10+ Cited Publications	Complement System	Cancer
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to *NRP1* b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .

HY-10228

Motesanib 4 Publications Verification AMG 706	c-Kit VEGFR	Cancer
Motesanib (AMG 706) is a potent ATP-competitive inhibitor of *VEGFR1/2/3* with IC₅₀s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.

HY-10331A

Regorafenib monohydrate 85+ Cited Publications BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for *VEGFR1/2/3, PDGFRβ, Kit, RET* and *Raf-1*, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity ^[1].

HY-10207

Dovitinib lactate 10+ Cited Publications CHIR-258 lactate; TKI-258 lactate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively ^[1].

HY-10229

Motesanib Diphosphate 4 Publications Verification AMG 706 Diphosphate	c-Kit VEGFR	Cancer
Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of *VEGFR1/2/3* with IC₅₀s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.

HY-50904S2

Nintedanib-d8 BIBF 1120-d₈	Isotope-Labeled Compounds PDGFR VEGFR FGFR	Cancer
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10337

Brivanib 2 Publications Verification BMS-540215	VEGFR Autophagy	Cancer
Brivanib (BMS-540215) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β ^[1].

HY-13308

Regorafenib Hydrochloride 85+ Cited Publications BAY 73-4506 hydrochloride	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for *VEGFR1/2/3, PDGFRβ, Kit, RET* and *Raf-1* with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively ^[1].

HY-10336

Brivanib (alaninate) 2 Publications Verification BMS-582664	VEGFR Autophagy	Cancer
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

HY-10977A

Tivozanib hydrochloride hydrate 5+ Cited Publications AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate	VEGFR	Cancer
Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy ^[1].

HY-10981S

Lenvatinib-d4 E7080-d₄	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-101219

*VEGFR-IN-1*	VEGFR c-Kit EGFR	Cancer
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, *Flt-1, c-Kit, EGF-R*, and c-Src, respectively ^[1].

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-I0678

Regorafénib N-oxyde (M2)	Drug Metabolite PDGFR	Cancer
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a *VEGF* inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of *VEGF-A* (K_d = 0.5 pM), *VEGF-B* (K_d = 8 pM), *VEGF-C, and PlGF* (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of *VEGF, TNF-α* and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) ^[1] .

HY-109020

Acrizanib 1 Publications Verification LHA510	VEGFR	Others
Acrizanib (LHA510) is a *VEGFR-2* inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-10981R

Lenvatinib (Standard) E7080 (Standard)	Reference Standards VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-133980A

O-Demethyl Lenvatinib hydrochloride	Drug Metabolite	Cancer
O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities ^[1] .

HY-50904S1

Nintedanib-13C,d3 BIBF 1120-¹³C,d₃	Isotope-Labeled Compounds PDGFR VEGFR FGFR	Cancer
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized *VEGFR-1* extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human *PD-L1* heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a *PD-L1* inhibitor and a *VEGF* inhibitor ^[1] .

HY-18711

SCR-1481B1 free base MetatINib free base; c-Met INhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-133980

O-Demethyl Lenvatinib	Drug Metabolite	Cancer
O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively ^[1].

HY-120640

BMS-605541	VEGFR PDGFR	Cancer
BMS-605541 is a selective and orally active inhibitor of *VEGFR-2* kinase with an IC₅₀ value of 23 nM and K_i value of 49 nM. BMS-605541 inhibits the activity of *Flk-1, VEGFR-1* and PDGFR-β with IC₅₀ values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research ^[1].

HY-50904S

Nintedanib-d3 BIBF 1120-d₃	PDGFR VEGFR FGFR	Cancer
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904R

Nintedanib (Standard) BIBF 1120 (Standard)	Reference Standards PDGFR VEGFR FGFR	Cancer
Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10230S

Midostaurin-d5 PKC412-d₅; CGP 41251-d₅	Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit	Cancer
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM ^[1].

HY-I0678S

Regorafénib N-oxyde-d3 (M2)	PDGFR Drug Metabolite	Cancer
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2 ^[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

HY-11106R

Nintedanib esylate (Standard) BIBF 1120 esylate (Standard)	Reference Standards PDGFR VEGFR FGFR	Cancer
Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50905R

Dovitinib (Standard) CHIR-258 (Standard); TKI258 (Standard)	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Reference Standards	Cancer
Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity ^[1] .

HY-177612

AGN-745 AGN-211745; Sirna-027	VEGFR	Others
AGN-745 is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

HY-10981S1

Lenvatinib-d5 E7080-d₅	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-10981AR

Lenvatinib mesylate (Standard) E7080 mesylate (Standard)	Reference Standards VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-10981S2

Lenvatinib-15N,d4 E7080-¹⁵N,d₄	VEGFR c-Kit FGFR RET PDGFR Isotope-Labeled Compounds	Cancer
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-13308R

Regorafenib Hydrochloride (Standard) BAY 73-4506 hydrochloride (Standard)	VEGFR Autophagy PDGFR Raf RET Reference Standards	Cancer
Regorafenib (Hydrochloride) (Standard) is the analytical standard of Regorafenib (Hydrochloride). This product is intended for research and analytical applications. Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively ^[1].

HY-164387

Sutetinib	EGFR PDGFR VEGFR	Cancer
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as *VEGFR* (K_i= 0.009 µM for VEGFR-1/2/3), PDGFR (K_i= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo ^[1].

Cat. No.	Product Name	Target	Research Area	Image

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a *VEGF* inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of *VEGF-A* (K_d = 0.5 pM), *VEGF-B* (K_d = 8 pM), *VEGF-C, and PlGF* (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of *VEGF, TNF-α* and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) ^[1] .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized *VEGFR-1* extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human *PD-L1* heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a *PD-L1* inhibitor and a *VEGF* inhibitor ^[1] .

HY-P990147

*Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a)*	VEGFR	Others
Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is an anti-mouse *VEGFR-2* IgG2a monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) is a chimeric antibody of the original DC101 antibody (HY-P990106). Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) can react with mouse VEGFR-2 .

HY-P991430

RO5323441 TB-403	VEGFR	Cancer
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to *VEGFR-1* (IC₅₀ values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity ^[1].

HY-P991132

Efclarofusp alfa	VEGFR	Cardiovascular Disease Cancer
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of *VEGFR-1* and *VEGFR-2* regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer Source Classification	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

Cat. No.	Product Name	Chemical Structure

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM ^[1].

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2 ^[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively ^[1] .

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

HY-10977S

Tivozanib-d6
Tivozanib-d₆ (AV-951-d₆) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy ^[1] .

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM ^[1] . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Cat. No.	Product Name		Classification

HY-177612

AGN-745 AGN-211745; Sirna-027		siRNAs siRNA drugs
AGN-745 is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

HY-177612A

AGN-745 sodium AGN-211745 sodium; Sirna-027 sodium		siRNAs siRNA drugs
AGN-745 sodium is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks